GLP-1 Weight Loss Projection Calculator
Project your potential weight loss on semaglutide or tirzepatide based on average results from published clinical trials (STEP and SURMOUNT).
Evidence-based
Projections derived from peer-reviewed clinical trial results.
Fully cited
Every data point linked to NEJM and Lancet publications.
10,000+ trial participants
Data from large-scale randomized controlled trials.
How this calculator works
This tool uses average weight-loss percentages from landmark GLP-1 receptor agonist clinical trials to project your potential results over time. The trajectory is modeled as a logarithmic curve where most weight loss occurs in the first 6 months, then gradually plateaus — matching real-world treatment patterns.
Semaglutide (Wegovy): The STEP program studied 2.4 mg once-weekly semaglutide in adults with and without type 2 diabetes. STEP 1 showed 14.9% average body weight loss at 68 weeks in patients without T2D. STEP 2 showed 9.6% in patients with T2D.
Tirzepatide (Zepbound/Mounjaro): The SURMOUNT program studied tirzepatide at 5, 10, and 15 mg doses. SURMOUNT-1 showed dose-dependent losses of 15.0% to 20.9% at 72 weeks in patients without T2D. SURMOUNT-2 showed 14.7% at the 15 mg dose in patients with T2D.
Important context: These are population averages from controlled trials with strict inclusion criteria. Your results may differ based on starting BMI, metabolic health, diet, exercise, medication adherence, and genetics.